About the Company
lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LYRA News
Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
There are several stocks that passed through the screen and Lyra Therapeutics, Inc. (LYRA) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. A solid ...
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
Lyra Therapeutics, Inc. (LYRA) shares rallied 6.9% in the last trading session to close at $5.30. This move can be attributable to notable volume with a higher number of shares being traded than ...
Lyra Therapeutics Inc Ordinary Shares LYRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company ...
Lyra Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...